Genotype-phenotype discrepancy among family members carrying a novel glucokinase mutation: insights into the interplay of GCK-MODY and insulin resistance
Shuhui Ji, Hua Shu, Zhao Hongqiang, Yuanyuan Ye, Xuan Liu, Shanshan Chen, Ying Yang, Wenli Feng, Jingting Qiao, Jinyang Zhen, Xiong Yang, Ziyue Zhang, Yu Fan, Yadi Huang, Qing He, Minxian Wang, Kunlin Wang, Ming LiumedRxiv2024 · DOI
This study provides a fascinating look at why "simple" genetic diseases are rarely simple. By investigating a family with a novel mutation in the glucokinase gene, researchers demonstrate that the severity of monogenic diabetes (MODY) is not just about the single "broken" gene, but rather the interplay between that mutation and a patient’s broader polygenic risk for insulin resistance.
TL;DR
Researchers identified a novel glucokinase mutation (GCK-Q26L) that causes MODY, but found its clinical impact varied wildly between family members. By combining human genetics with a custom knock-in mouse model, they proved that a high polygenic risk score (PRS) for insulin resistance can transform a typically mild condition into a severe diabetic phenotype.
What Problem Does This Paper Address?
Maturity-Onset Diabetes of the Young (MODY) is traditionally classified as a monogenic disorder—meaning a mutation in a single gene is responsible for the disease. Specifically, GCK-MODY (MODY 2) is usually a mild, non-progressive form of hyperglycemia because the "glucose sensor" (glucokinase) in the pancreas is set to a slightly higher threshold.
However, clinicians often see "genotype-phenotype discrepancies," where family members with the exact same mutation have vastly different symptoms. This paper addresses the "why" behind this variation. The authors investigate a proband (the first patient studied) who presented with severe diabetes, ketosis, and dyslipidemia, while her father—who carried the same mutation—had only the typical mild symptoms of GCK-MODY.
Methods
The study employed a multi-level approach to bridge the gap between clinical observation and molecular mechanism:
Human Genetics: The team used Whole-Exome Sequencing (WES) and Sanger sequencing to identify the novel mutation. Crucially, they calculated Polygenic Risk Scores (PRS) for insulin resistance to evaluate the broader genetic background of the family members.
Animal Modeling: They developed a global knock-in mouse model harboring the specific GCK-Q26L mutation in both heterozygous and homozygous states to confirm its pathogenicity.
Functional Assays: To understand the mechanism, they performed:
GSIS (Glucose-Stimulated Insulin Secretion): Testing how isolated pancreatic islets respond to different glucose concentrations.
Pharmacological Testing: Evaluating the efficacy of Dorzagliatin (a glucokinase activator) and Liraglutide (a GLP-1 receptor agonist) in the mutant mice.
Datasets
Family Trio: Clinical and genetic data from the proband, her father, and her mother.
UK Biobank: Data from 424,068 individuals was used to validate the association between the PRS and insulin resistance markers (like the TG/HDL-C ratio).
1000 Genomes Project: East Asian samples were used as a reference population to calculate and rank the family's polygenic risk.
gnomAD (v4.1.0): Used to confirm that the identified mutation was previously unreported in the general population.
Key Insights and Ideas
The "Double Hit" Hypothesis: The proband’s severe symptoms were the result of a "perfect storm." She inherited the GCK-Q26L mutation from her father (the monogenic hit) and a very high polygenic risk for insulin resistance from her mother (the polygenic hit).
The Mother’s Hidden Risk: While the mother did not have the GCK mutation, her PRS for insulin resistance was in the top 1.09% of the population. The proband inherited this high-risk background, which exacerbated the effects of the GCK mutation.
A Shifted Thermostat: Functional tests showed the mutation doesn't "kill" insulin production; instead, it shifts the glucose-sensing curve to the right. The pancreas is capable of secreting insulin, but it requires much higher blood sugar levels to "trigger" the release.
Precision Treatment: The study suggests that for patients with this specific "interplay" phenotype, dual-action treatments are effective. Glucokinase activators (GKAs) fix the "sensor" directly, while GLP-1RAs help boost the insulin response downstream.
Key Results
Mutation Identified: The novel variant c.77A>T (p.Q26L) was confirmed as pathogenic.
Clinical Discrepancy: The proband had an HbA1c of 12.5% (severe), while her father’s was only 7.7% (mild).
Mouse Phenotype: Heterozygous mutant mice replicated the mild human MODY phenotype (impaired glucose tolerance but normal weight), while homozygous mice showed severe diabetes.
Mechanism Confirmed: Mutant islets showed a significantly blunted insulin response to glucose, but responded normally to potassium chloride, proving the defect was specifically in the glucose-sensing pathway.
Therapeutic Success: In mice, Dorzagliatin restored the glucose threshold for insulin secretion, significantly lowering fasting blood glucose.
Limitations and Future Work
Model Constraints: While the mouse model replicated the GCK-MODY phenotype well, mice do not perfectly mirror human polygenic backgrounds or lifestyle factors.
Sample Size: The study focuses on a single family. Larger cohorts are needed to establish standardized guidelines for how PRS should be used to adjust MODY management.
Long-term Effects: The study did not explore the long-term impact of these treatments on beta-cell exhaustion or chronic complications.
Future Direction: The authors suggest that routine diabetes care should eventually incorporate both monogenic screening and polygenic risk assessments to provide truly personalized medicine.
Summary updated
Abstract
Abstract Aims/Hypothesis Heterozygous inactivating mutations in the glucokinase (GCK) gene are known to cause maturity-onset diabetes of the young (GCK-MODY). We identified a novel variant of uncertain significance (VUS) GCK mutation (c.77A>T, p.Q26L) in two family members presenting markedly different severities of diabetic phenotypes. This study aimed to elucidate the potential diabetogenic effect of GCK-Q26L and to explore the mono- and poly-genetic background attributing to different diabetes phenotypes. Methods Whole-exome sequencing (WES) and genetic analyses, including polygenic risk score (PRS) assessments, were performed in three members of a family with early-onset diabetes. To elucidate the impact of the GCK-Q26L mutation on glucose homeostasis, a global knock-in mouse model harboring this mutation in both heterozygous and homozygous states was generated. Insulin content and insulin secretion response to glucose and potassium were evaluated in isolated islets. Furthermore, the effects of dorzagliatin (a glucokinase activator, GKA) and liraglutide (a glucagon like peptide 1 receptor agonist, GLP-1RA) on glucose tolerance and insulin secretion were assessed in GCK-Q26L mutant mice. Results The proband, who inherited the GCK-Q26L mutation from her father (presenting with non-progressive, mildly elevated blood glucose), exhibited severe diabetic phenotypes including polydipsia, polyuria, polyphagia, weight loss, and ketosis, accompanied by significant dyslipidemia. Genetic analyses revealed that the proband’s severe phenotypes and metabolic profiles were associated with a high polygenic risk score (PRS) for insulin resistance that was inherited from her mother. Global heterozygous GCK-Q26L knock-in mice showed a mild increased fasting blood glucose, impaired glucose tolerance (IGT), and decreased serum insulin. Homozygous GCK-Q26L mice presented more severe phenotypes compared to their heterozygous counterparts, confirming the diabetogenic nature of the GCK-Q26L mutation. Further analyses indicated that GCK-Q26L did not affect insulin sensitivity and islet insulin content. However, GCK-Q26L blunted islet responsiveness to different glucose concentrations and markedly impaired glucose-stimulated insulin secretion (GSIS) without affecting potassium chloride-stimulated insulin secretion (KSIS) and glucose inhibitory effects on glucagon secretion. Both GKA and GLP-1RA enhanced insulin secretion and improved glucose tolerance in mutant mice. Conclusions/Interpretation This study demonstrates that GCK-Q26L is a GCK-MODY causing mutation. The interplay of GCK-Q26L with a high PRS for insulin resistance contributes to severe diabetic phenotypes. The findings not only expend the list of GCK-MODY causing mutations originally classified as VUS mutations, but also provides insights into interactions of GCK-MODY with polygenic risks of type 2 diabetes, highlighting the importance of considering polygenic backgrounds in the assessment and management of monogenic diabetes. Research in Context What is already known about this subject? Heterozygous inactivating mutations in the GCK gene cause GCK-MODY, an autosomal dominant disorder characterized by mild hyperglycemia present from birth. Insulin resistance can be influenced by multiple genetic polymorphisms, contributing to varying diabetes phenotypes. What is the key question? Is the newly discovered GCK mutation pathogenic? Do the interactions between the GCK mutation and PRS for insulin resistance influence the phenotypic variability in patients carrying GCK-MODY? What are the new findings? The study demonstrates GCK-Q26L impairs GSIS and causes diabetes, establishing it as a novel GCK-MODY causing mutation originally classified as a VUS mutation. The GCK-Q26L knock - in mouse line replicates phenotypes of GCK-MODY in humans, establishing it as an excellent model for GCK-MODY. The phenotypic variability in patients with GCK-MODY can be significantly influenced by high-risk genetic predisposition of type 2 diabetes. Both GKA and GLP-1RA enhance insulin secretion and improve glucose tolerance in GCK-Q26L mutant mice, suggesting that they are favorite options for treatment of patients with GCK-MODY and insulin resistance. How might this impact clinical practice in the foreseeable future? Recognizing atypical presentations of monogenic diabetes influenced by polygenic factors can enhance diagnostic accuracy and personalized management. Genetic testing and polygenic risk score assessments can help identify patients at higher risk of severe phenotypes, allowing for earlier and more targeted interventions.
BibTeX
@misc{ji2024genotype,
author = {Shuhui Ji and Hua Shu and Zhao Hongqiang and Yuanyuan Ye and Xuan Liu and Shanshan Chen and Ying Yang and Wenli Feng and Jingting Qiao and Jinyang Zhen and Xiong Yang and Ziyue Zhang and Yu Fan and Yadi Huang and Qing He and Minxian Wang and Kunlin Wang and Ming Liu},
title = {{Genotype-phenotype discrepancy among family members carrying a novel glucokinase mutation: insights into the interplay of GCK-MODY and insulin resistance}},
year = {2024},
doi = {10.1101/2024.08.13.24311668},
howpublished = {medRxiv},
}